🚨 Everything is back in stock — all peptides available now 🚨

Tirzepatide vs semaglutide

Written and maintained by the AVERON Research Desk · Last reviewed September 2026

Tirzepatide and semaglutide are the two most widely used compounds in the modern weight-management category. Unlike most comparisons in this field, these two have been tested directly against each other in a randomised trial, which means the comparison rests on real evidence rather than inference.

How they work

Semaglutide activates one receptor: GLP-1. It is sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for weight management. It was developed by Novo Nordisk.

Tirzepatide activates two: GIP and GLP-1. It is sold as Mounjaro for type 2 diabetes and Zepbound for weight management. It was developed by Eli Lilly.

The head-to-head trial

SURMOUNT-5, published by Louis Aronne and colleagues in the New England Journal of Medicine in 2025, enrolled adults with obesity and without diabetes and randomly assigned them to tirzepatide or semaglutide, each at the highest dose participants could tolerate, for 72 weeks.

Average weight change was −20.2% with tirzepatide and −13.7% with semaglutide. Tirzepatide produced significantly greater weight loss.

Side by side

TirzepatideSemaglutide
ReceptorsGIP, GLP-1GLP-1
Brand namesMounjaro, ZepboundOzempic, Wegovy, Rybelsus
ManufacturerEli LillyNovo Nordisk
Key obesity trialSURMOUNT-1: −20.9% at 72 weeksSTEP 1: −14.9% at 68 weeks
Head-to-head (SURMOUNT-5)−20.2%−13.7%
Proven cardiovascular benefit in obesityTrials ongoingYes, SELECT trial
Approved in IndonesiaYesYes
Anti-dopingMonitoring Program, not prohibitedMonitoring Program, not prohibited

Where semaglutide has the edge

Weight loss is not the only measure. Semaglutide is the one of the two that has already been shown, in a dedicated trial in people with obesity but without diabetes, to reduce major cardiovascular events. In the SELECT trial, published in 2023, it reduced the risk of cardiovascular death, heart attack or stroke by 20% in people with existing cardiovascular disease. Semaglutide also has the longer safety record, having been approved since 2017.

Side effects

Both cause mainly gastrointestinal effects — nausea, diarrhoea, vomiting and constipation — most often while doses are increased. Both carry the same class boxed warning about thyroid C-cell tumours based on rodent findings, and both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Pancreatitis and gallbladder disease are listed risks for both.

What neither does

Neither preserves muscle specifically; part of the weight lost with both is lean mass. Weight tends to return after either is stopped. And research-grade material of either is not the registered, branded medicine.

Frequently asked questions

In the head-to-head SURMOUNT-5 trial, tirzepatide: −20.2% compared with −13.7% over 72 weeks.

No. Mounjaro is tirzepatide, a dual GIP and GLP-1 agonist. Ozempic is semaglutide, a GLP-1 agonist.

Semaglutide has been shown to reduce major cardiovascular events in the SELECT trial. Equivalent trials for tirzepatide in obesity are ongoing.

Yes. Both are registered with BPOM.

No. Both are on WADA's Monitoring Program, not the Prohibited List.

Doses mentioned on this page are the arms of published trials, given to describe their results. They are not guidance.

Sources

  1. Aronne LJ, Horn DB, le Roux CW, et al.. Tirzepatide as compared with semaglutide for the treatment of obesity. New England Journal of Medicine, 2025. Link
  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 2022;387:205–216. Link
  3. Wilding JPH, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 2021;384:989–1002. Link
  4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 2023;389:2221–2232. Link

Related pages

...